Cargando…

A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data

The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classific...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohail, Muhammad Noman, Jiadong, Ren, Uba, Musa Muhammad, Irshad, Muhammad, Iqbal, Wasim, Arshad, Jehangir, John, Antony Verghese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626127/
https://www.ncbi.nlm.nih.gov/pubmed/31300715
http://dx.doi.org/10.1038/s41598-019-46631-9
_version_ 1783434510526840832
author Sohail, Muhammad Noman
Jiadong, Ren
Uba, Musa Muhammad
Irshad, Muhammad
Iqbal, Wasim
Arshad, Jehangir
John, Antony Verghese
author_facet Sohail, Muhammad Noman
Jiadong, Ren
Uba, Musa Muhammad
Irshad, Muhammad
Iqbal, Wasim
Arshad, Jehangir
John, Antony Verghese
author_sort Sohail, Muhammad Noman
collection PubMed
description The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classification results to forecast cost/benefit ratio in diabetes mellitus patients along with prevalence. In total 108 invasive and non-invasive medical features are considered from 251 patients for assessment, and the real-time data are gathered from Pakistan over a time span of June 2017 to April 2018. The results indicate that J48 classifiers achieved the best accuracy of (99.28%), whereas, error rate (0.08%), Kappa stats, PRC, and MCC are (0.98%), precision, recall, and F-matrix are (0.99%). In addition, true positive rate is (0.99%) and false positive is (0.08%). The regression forecast decision indicates blood pressure and glucose level are key features for diabetes. The cost/benefit matrix indicates two predictions for positive test with accuracy (66.68%) and (30.60%), and key attributes with total Gain (118.13%). The study confirmed the proposed prediction is practical for screening of diabetes mellitus patients at the initial stage without invasive medical tests and found effectual in the early diagnosis of diabetes.
format Online
Article
Text
id pubmed-6626127
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66261272019-07-21 A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data Sohail, Muhammad Noman Jiadong, Ren Uba, Musa Muhammad Irshad, Muhammad Iqbal, Wasim Arshad, Jehangir John, Antony Verghese Sci Rep Article The increasing ratio of diabetes is found risky across the planet. Therefore, the diagnosis is important in population with extreme risk of diabetes. In this study, a decision-making classifier (J48) is applied over a data-mining platform (Weka) to measure accuracy and linear regression on classification results to forecast cost/benefit ratio in diabetes mellitus patients along with prevalence. In total 108 invasive and non-invasive medical features are considered from 251 patients for assessment, and the real-time data are gathered from Pakistan over a time span of June 2017 to April 2018. The results indicate that J48 classifiers achieved the best accuracy of (99.28%), whereas, error rate (0.08%), Kappa stats, PRC, and MCC are (0.98%), precision, recall, and F-matrix are (0.99%). In addition, true positive rate is (0.99%) and false positive is (0.08%). The regression forecast decision indicates blood pressure and glucose level are key features for diabetes. The cost/benefit matrix indicates two predictions for positive test with accuracy (66.68%) and (30.60%), and key attributes with total Gain (118.13%). The study confirmed the proposed prediction is practical for screening of diabetes mellitus patients at the initial stage without invasive medical tests and found effectual in the early diagnosis of diabetes. Nature Publishing Group UK 2019-07-12 /pmc/articles/PMC6626127/ /pubmed/31300715 http://dx.doi.org/10.1038/s41598-019-46631-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Sohail, Muhammad Noman
Jiadong, Ren
Uba, Musa Muhammad
Irshad, Muhammad
Iqbal, Wasim
Arshad, Jehangir
John, Antony Verghese
A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title_full A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title_fullStr A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title_full_unstemmed A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title_short A hybrid Forecast Cost Benefit Classification of diabetes mellitus prevalence based on epidemiological study on Real-life patient’s data
title_sort hybrid forecast cost benefit classification of diabetes mellitus prevalence based on epidemiological study on real-life patient’s data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626127/
https://www.ncbi.nlm.nih.gov/pubmed/31300715
http://dx.doi.org/10.1038/s41598-019-46631-9
work_keys_str_mv AT sohailmuhammadnoman ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT jiadongren ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT ubamusamuhammad ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT irshadmuhammad ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT iqbalwasim ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT arshadjehangir ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT johnantonyverghese ahybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT sohailmuhammadnoman hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT jiadongren hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT ubamusamuhammad hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT irshadmuhammad hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT iqbalwasim hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT arshadjehangir hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata
AT johnantonyverghese hybridforecastcostbenefitclassificationofdiabetesmellitusprevalencebasedonepidemiologicalstudyonreallifepatientsdata